Tian Tian
Research group
- Translational oncology in upper gastrointestinal cancers Junior group leader (R3B)
About me
After medical training (MD), Dr Tian Tian completed his PhD studies at the Institut Pasteur de Lille and subsequently conducted postdoctoral research at the Centre for Genomic Regulation in Barcelona, focusing on transcriptional and epigenetic regulation in cancer cell plasticity. His current research combines molecular oncology, patient-derived models, and multi-omics approaches to advance precision medicine in pancreaticobiliary and gastroesophageal cancers. His research is currently supported by national and European funding, together with close collaborations with pharmaceutical companies
Featured publications
-
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.
Authors:Reference: CANCER CELL 2026. -
Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis
Authors:Reference: JHEP Rep 2026. -
Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort
Authors:Reference: ESMO Open 2026. -
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy☆
Authors:Reference: CANCER TREATMENT REVIEWS 2025. -
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors.
Authors:Reference: ANNALS OF ONCOLOGY 2025. -
From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors.
Authors:Reference: Signal Transduct Target Ther 2025. -
Stromal barriers to the abscopal effect
Authors:Reference: CANCER CELL 2025. -
Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy
Authors:Reference: CLINICAL CANCER RESEARCH 2024. -
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Authors:Reference: Science Translational Medicine 2024. -
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors:Reference: CLINICAL CANCER RESEARCH 2023.
Featured Projects
-
Patient-derived models for the research and evaluation of discovery and innovation in combination therapies for biliary tract cancer (PREDICT-BC)
Principal investigator: Tian Tian TaoFunder: EU TRANSCAN-3 JTC2024Duration: 01/10/2025 - 30/09/2028 -
Desarrollo de nuevas estrategias para mejorar las terapias dirigidas del colangiocarcinoma
Principal investigator: Tian Tian TaoFunder: Ministerio de Ciencia, Innovación y UniversidadesCode: PID2023_146827OB-I00Duration: 01/01/2025 - 31/12/2027 -
Hacia una terapia de receptores de antígenos quiméricos de próxima generación para el colangiocarcinoma (TARQ-CCA)
Funder: Fundació AstraZenecaDuration: 01/11/2024 - 31/12/2026 -
Deciphering epigenetic features hidden in the plasma of cholangiocarcinoma patients
Principal investigator: Tian Tian TaoFunder: FERO Foundation XXII edition PrizeDuration: 01/01/2023 - 31/12/2024 -
Targeting chromatin-associated proteins in cancers
Principal investigator: Tian Tian TaoFunder: Ministerio de Ciencia, Innovación y UniversidadesCode: RYC2020-029098-IDuration: 01/05/2022 - 30/04/2027
